Drugs affected by CHRNA5
About CHRNA5
CHRNA5 codes for part of the nicotinic acetylcholine receptor in the brain. The rs16969968 variant changes the receptor's response to nicotine and is one of the strongest known genetic predictors of heavy smoking and lung cancer risk. It also modifies how well people quit on varenicline or bupropion versus nicotine replacement alone.[1]
Heavy smokers who carry the high-risk allele appear to benefit more from prescription smoking cessation (varenicline or bupropion) than from over-the-counter nicotine patches alone.
What we test for CHRNA5
Gene2Rx uses definitions covering 2 named CHRNA5 alleles, built from 1 variant in Gene2Rx definitions. Results depend on the variants available in your upload.
- Named alleles
- 2
- Defined variants
- 1
- Source
- Gene2Rx definitions
- Genome build
- GRCh38
- Normal Function 1
- Increased Risk 1
What do these allele names mean?
CHRNA5 alleles are named by the underlying DNA variant rather than a star number. For example, c.61C>T describes a single base change at position 61 of the coding sequence.
DNA variant labels identify sequence differences. Their interpretation depends on the particular gene, the evidence, and the variants that can be assessed in your data. A DNA result does not directly measure enzyme activity.
The source of these definitions is listed above. Missing variants or incomplete coverage can leave a result indeterminate.
Medications with CHRNA5 information
This list contains 1 medication with CHRNA5 information from the sources shown below. Evidence and report eligibility differ by drug; each page explains its scope and limitations.
References
- PharmGKB / Stanford University. PharmGKB: The Pharmacogenomics Knowledge Base. pharmgkb.org
Explore CHRNA5 in your report
Informational only, not medical advice. The presence of a CHRNA5 pharmacogenetic guideline does not mean every patient needs to change their dose. Never start, stop, or change a medication without talking to your prescribing clinician.